E
Eleanor McFadden
Researcher at Harvard University
Publications - 10
Citations - 7063
Eleanor McFadden is an academic researcher from Harvard University. The author has contributed to research in topics: Breast cancer & Trastuzumab. The author has an hindex of 8, co-authored 10 publications receiving 5988 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Journal ArticleDOI
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron,Martine Piccart-Gebhart,Richard D. Gelber,Richard D. Gelber,Marion Procter,Aron Goldhirsch,Evandro de Azambuja,Gilberto de Castro,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,N. Al-Sakaff,S. Lauer,Eleanor McFadden,Brian Leyland-Jones,Richard Bell,Mitch Dowsett,Christian Jackisch +18 more
TL;DR: 1 year of adjuvant trastuzumab after chemotherapy for patients with HER2-positive early breast cancer significantly improves long-term disease-free survival, compared with observation.
Journal ArticleDOI
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew Tutt,Judy Garber,Bella Kaufman,Giuseppe Viale,Debora Fumagalli,Priya Rastogi,Priya Rastogi,Richard D. Gelber,Evandro de Azambuja,Anitra Fielding,Judith Balmaña,Susan M. Domchek,Karen A. Gelmon,Simon J. Hollingsworth,Larissa A. Korde,Barbro Linderholm,Hanna Bandos,Hanna Bandos,Elżbieta Senkus,Jennifer Marie Suga,Zhimin Shao,Andrew W. Pippas,Zbigniew Nowecki,Tomasz Huzarski,Patricia A. Ganz,Peter Lucas,Peter Lucas,Nigel Baker,Sibylle Loibl,Robin McConnell,Martine Piccart,Rita K. Schmutzler,Guenther G. Steger,Joseph P. Costantino,Amal Arahmani,Norman Wolmark,Norman Wolmark,Eleanor McFadden,Vassiliki Karantza,Sunil R. Lakhani,Greg Yothers,Greg Yothers,Christine Campbell,Charles E. Geyer +43 more
TL;DR: In this paper, a poly(adenosine diphosphate-ribose) polymerase inhibitor was proposed to target cancers with defects in homologous recombination repair by synthetic lethality.
Journal ArticleDOI
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial
Aron Goldhirsch,Richard D. Gelber,Martine Piccart-Gebhart,Evandro de Azambuja,Marion Procter,Thomas M. Suter,Christian Jackisch,David Cameron,Harald A. Weber,Dominik Heinzmann,Lissandra Dal Lago,Eleanor McFadden,Mitch Dowsett,Michael Untch,Luca Gianni,Richard Bell,Claus Henning Köhne,A. Vindevoghel,Martin Andersson,A Murray Brunt,Douglas Otero-Reyes,Santai Song,Ian E. Smith,Brian Leyland-Jones,José Baselga +24 more
TL;DR: 2 years of adjuvant trastuzumab is not more effective than is 1 year of treatment for patients with HER2-positive early breast cancer, and 1year of treatment provides a significant disease-free and overall survival benefit compared with observation.
Journal ArticleDOI
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Martine Piccart-Gebhart,Eileen Holmes,Jośe Baselga,Evandro de Azambuja,Amylou C. Dueck,Giuseppe Viale,Jo Anne Zujewski,Aron Goldhirsch,A Armour,Kathleen I. Pritchard,Ann E. McCullough,Stella Dolci,Eleanor McFadden,Andrew P. Holmes,Liu Tong-hua,Holger Eidtmann,Phuong Dinh,Serena Di Cosimo,Nadia Harbeck,Sergei Tjulandin,Young-Hyuck Im,Chiun-Sheng Huang,Véronique Diéras,David W. Hillman,Antonio C. Wolff,Christian Jackisch,István Láng,Michael Untch,Ian E. Smith,Frances M. Boyle,Binghe Xu,Henry L. Gomez,Thomas M. Suter,Richard D. Gelber,Edith A. Perez +34 more
TL;DR: Adjuvant treatment that includes L did not significantly improve DFS compared with T alone and added toxicity, and one year of adjuvant T remains standard of care.